6 Stocks that nose-dived – RCR, WTC, RAC, PMP, HGM and VRS

stocks dive

RCR TOMLINSON LIMITED (ASX: RCR)To raise approximately $100 million, RCR has come up with an underwritten 1 for 1.65 pro rata non-renounceable entitlement offer, at the price of $1.00 per new share. For the year ended 30 June 2018, the company reported underlying EBIT loss of $4.2 million, and a statutory net loss after tax of $16.1 million. As at 30 June 2018, RCR held cash and cash equivalents of $89.9 million. The company has a negative EPS of -0.100 AUD which is impacting the profits. Revenue from continuing operations of $1,998.5 million has been reported by RCR. The stock is currently under the suspended status. However, the stock was last trading at a market price of $1.205 and had a daily price change of -$1.595 or -56.964%, it is currently near its 52-week low for the above reasons. In the last 12 months, the stock has undergone a performance change of a -25.53%. [optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

WISETECH GLOBAL LIMITED (ASX: WTC)Andrew Harrison, a new independent nonexecutive chairperson has been recently appointed by the company. Compared to FY17 the company reported a revenue growth of $221.6 million for FY18 which is up by 44%, while EBITDA went up by 45% for FY18. Also, given the healthy global business performance compared to the others the NPAT was up 28%. Over the period of 5 years from FY 14 and FY 18 the company has a 41% CAGR. Given the overall growth in the technology sector which is doing extremely well the stock has seen a daily price change of $0.400 and a percentage change of 1.857% as at August 30, 2018, the stock was trading at a market price of $21.940. In the last 12 months, the stock has undergone a performance change of a 170.94%.

RACE ONCOLOGY LTD (ASX: RAC) – Race’s goal is to create value for investors in three ways; 1) Move Bisantrene towards FDA approval for adult AML 2) Through Named Patient Programs Generate revenues outside the US 3) Through a targeted pediatric development program, secure a tradable priority review voucher. However, after income tax the operating loss amounted to $6,306,446 where net cash used in operating activities was $3,869,392. The company has not paid any dividends nor are they payable any time soon. The company had cash reserves of approx. $3.7m at the end of 30 June 2018. For the year ended 30 June 2018 the company incurred a loss of $6,306,446 and the financial report has been prepared on a going concern basis. With a daily price change of -$0.005 and a percentage change of -3.846% as at August 30, 2018, due to the losses incurred the stock was trading lower at a market price of $0.125. In the last 12 months, the stock has undergone a performance change of a -63.89%.

PMP LIMITED (ASX: PMP) – From the previous corresponding period, sales are down $108 million on a like for like basis. The company had a net loss of $43.8 million which is $82.6 million lower the previous corresponding period largely down to reduction in significant items. On a 12 months basis EBITDA was down by $7.8 million for the full FY18 year. The distribution Australia revenue was down by $85.8 million from pcp. Also, the net cash flow changed from ($10.7) million to ($12.6) million and the company maintains a disciplined approach to capex with an objective to maintain a conservative balance sheet. With a daily price change of -$0.035 and a percentage change of -14.583% as at August 30, 2018, the stock was trading lower on the losses, at a market price of $0.205. In the last 12 months, the stock has undergone a performance change of a -68.21%.

HIGH GRADE METALS LIMITED (ASX: HGM) – The Company holds A$3.57 million in cash with no debt at the end of the quarter. Schellgaden North Gold Project, Schellgaden South Gold Project, Goldeck-Siflitz Gold Project, Kreuzeck East Gold Project, Kreuzeck West Gold Project, Leogang, Gratlspitz, Seekar, Zinkwand, (Cobalt, Copper, Nickel) Project are some of the key projects. The company has a low P/E of 0.350 and EPS of 0.100 AUD which reflects better financial position compared to the peers. The company has not declared dividends during the year 2018. With a daily price change of -$0.003 and a percentage change of -8.571% as at August 30, 2018, the stock was trading at a market price of $0.032. In the last 12 months, the stock has undergone a performance change of a 34.62%.

VERIS LIMITED (ASX: VRS) – The company’s EBITDA from the continuing operations is up by 96% to $11.2m. The current cash at bank as at August 30, 2018 is $5.6m which portrays liquidity for Veris. It lately declared fully franked dividend of 0.5 cents per share to be paid in September 2018. The annual dividend yield is 2.22%. Net Profit After Tax Before Amortisation stands currently at $1.8 million for the year ending June 30, 2018. The basic and diluted loss per share has been 0.39 for 2018. Because of which the stock saw a daily price change of -$0.010 and a percentage change of –4.444% as at August 30, 2018 and was trading at a market price of $0.215. In the last 12 months, the stock has undergone a performance change of a 40.63%.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report